Skip to main content

Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.

IAS 2022

IAS 2022

  • Thursday, April 21, 2022
  • 9:00 AM – 9:55 AM ET
    Welcome & Opening Session: Collaborative Cases in IMIDs
  • 10:10 AM – 10:55 AM ET
    Beyond TNF Inhibitors: Optimizing IL-12/23 and IL-23 Inhibitors for Inflammatory Bowel Disease Therapy
  • 11:10 AM – 12:10 PM ET
    Innovation Theater (non-accredited): Defy Expectations: Clinical Review of a Now-Approved Therapy to Challenge Treatment Goals for TNFi-IR Patients with active Psoriatic Arthritis (PsA)
  • 12:25 PM – 1:10 PM ET
    Advances in Understanding Fatigue in IMIDs
  • 1:25 PM – 2:10 PM ET
    Deep Dive: Can We Achieve Remission?
  • 1:25 PM – 2:10 PM ET
    Deep Dive: Dual Targeting
  • 2:25 PM – 3:10 PM ET
    Immunologic Lessons from COVID19 for IMID care
  • 3:25 PM – 4:10 PM ET
    Overcoming the Challenges in Psoriatic Arthritis Diagnosis and Treatment
  • 4:25 PM – 5:10 PM ET
    How Covid 19 will change the world
  • Friday, April 22, 2022
  • 9:00 AM – 9:50 AM ET
    Challenging Case Scenarios
  • 10:05 AM – 10:50 AM ET
    Editors Focus - Best of 2021 Dermatology, Gastroenterology & Rheumatology
  • 11:05 AM – 12:05 PM ET
    Innovation Theater (non-accredited): Targeting Lupus Nephritis
  • 12:20 PM – 1:05 PM ET
    Disparities in Care in Immune Mediated Diseases
  • 1:20 PM – 2:05 PM ET
    Deep Dive: Combination Therapy Approaches
  • 1:20 PM – 2:05 PM ET
    Deep Dive: Wellness in the IMID patient population
  • 2:20 PM – 3:20 PM ET
    Innovation Theater (non-accredited): Taltz – An Overview of Efficacy and Safety in Plaque Psoriasis and Psoriatic Arthritis
  • 3:35 PM – 4:20 PM ET
    The Role of Interleukin Inhibitors in the Treatment of Moderate to Severe Psoriasis
  • 4:35 PM – 5:35 PM ET
    Innovation Theater (non-accredited): SAPHNELO™ (anifrolumab-fnia): The First-in Class Type 1 Interferon (IFN-1) Signaling Inhibitor
  • 5:50 PM – 6:35 PM ET
    Combined clinics - Combined Goals
  • 6:50 PM – 7:35 PM ET
    CAR-T Therapy for Autoimmune Diseases
  • Saturday, April 23, 2022
  • 9:00 AM – 9:50 AM ET
    IMIDs and Sexual Function and Dysfunction
  • 10:05 AM – 10:50 AM ET
    Addressing Clinical Challenges in Systemic Lupus Erythematosus: Improving Outcomes by Individualizing Care
  • 11:05 AM – 12:05 PM ET
    Innovation Theater (non-accredited): The Role of IL-6 in Inflammation, Rheumatoid Arthritis, and Cytokine Release Syndrome
  • 12:20 PM – 1:05 PM ET
    Vaccinations for IMIDS Patients: Guidelines, Risks and Benefits
  • 1:20 PM – 2:20 PM ET
    Innovation Theater (non-accredited): Challenging AD Expectations
  • 2:35 PM – 3:20 PM ET
    Current and Potential Clinical Roles for Oral JAK Inhibitors for the Treatment of IMIDs.
  • 3:35 PM – 4:20 PM ET
    Interdisciplinary Management of irAEs and the Evolving Role of Targeted Therapies
  • 4:35 PM – 5:35 PM ET
    Innovation Theater (non-accredited): A Conversation About Addressing Multiple Manifestations of Psoriatic Disease
  • 5:50 PM – 6:35 PM ET
    Cardiovascular risk and Immune-mediated Inflammatory Disorders
  • Sunday, April 24, 2022
  • 9:00 AM – 9:50 AM ET
    IMIDs and Sexual function and dysfunction
  • 10:05 AM – 10:50 AM ET
    Addressing Challenges in the Management of Inflammatory Bowel Disease: The Promise of Sphingosine-1-Phosphate Receptor Modulators
  • 11:05 AM – 12:05 PM ET
    Innovation Theater (non-accredited): TREMFYA (guselkumab): TREMFYA First In Class
  • 12:20 PM – 1:05 PM ET
    Alopecia Areata: Clinical Challenges and Emerging Treatments
  • 1:20 PM – 2:20 PM ET
    Innovation Theater (non-accredited): AbbVie Innovation Theater
  • 2:35 PM – 3:20 PM ET
    Biosimilars in the Treatment of IMIDs: A Potential Path to Improved Outcomes
  • 3:35 PM – 4:20 PM ET
    Leveraging Multiomics Data to Study Autoimmune Disease in the Era of Precision Medicine
  • 4:35 PM – 5:20 PM ET
    Placebo Nocebo and the Role of the Care Settings in Clinical Response 
  • Exclusive Content
  • On-Demand
    Cutaneous Manifestations of Sarcoidosis
  • On-Demand
    Evolving Endpoint for Regulators and Practitioners: Where Are We Going and How Do We Get There? 
  • On-Demand
    Future of Biologic Therapies for Vasculitis
  • On-Demand
    Hidradenitis Suppurativa: Clinical Pearls and Management Updates
  • On-Demand
    Managing C. Difficile in IBD
  • On-Demand
    Managing Extra-Intestinal Manifestations in IBD
  • On-Demand
    Managing Refractory Cutaneous Lupus Erythematosus
  • On-Demand
    Psoriasis for the Rheumatologist
  • On-Demand
    State of the Art: JAK Inhibitor Toxicity for IMIDS
  • On-Demand
    Systemic Sclerosis: Evidence-Based Treatments
  • On-Demand
    Treatment of IBD and Integrating Novel Therapies
  • On-Demand
    Understanding Behcet Syndrome
  • On-Demand
    Vitiligo: Clinical Characteristics, Optimizing Management, and Emerging Treatments